U.S. patent application number 16/794856 was filed with the patent office on 2020-08-20 for nasal filter pod.
The applicant listed for this patent is Resprana, Inc.. Invention is credited to Sophie Frank, Sukanya Goswami, Andrea McDonald, Jai Rathore, Micah Steiger, Marc-Aurelien Vivant.
Application Number | 20200261670 16/794856 |
Document ID | 20200261670 / US20200261670 |
Family ID | 1000004769002 |
Filed Date | 2020-08-20 |
Patent Application | download [pdf] |
![](/patent/app/20200261670/US20200261670A1-20200820-D00000.png)
![](/patent/app/20200261670/US20200261670A1-20200820-D00001.png)
United States Patent
Application |
20200261670 |
Kind Code |
A1 |
Frank; Sophie ; et
al. |
August 20, 2020 |
NASAL FILTER POD
Abstract
A nasal pod is described for dispensing a compound such as
asthma medication to air inhaled through the nose.
Inventors: |
Frank; Sophie; (San
Francisco, CA) ; Vivant; Marc-Aurelien; (Brooklyn,
NY) ; Steiger; Micah; (New York, NY) ;
Goswami; Sukanya; (Brooklyn, NY) ; Rathore; Jai;
(Madison, WI) ; McDonald; Andrea; (New York,
NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Resprana, Inc. |
New York |
NY |
US |
|
|
Family ID: |
1000004769002 |
Appl. No.: |
16/794856 |
Filed: |
February 19, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62807799 |
Feb 20, 2019 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
B01D 46/0028 20130101;
B01D 2279/40 20130101; A61M 2205/7545 20130101; B01D 46/0032
20130101; B01D 2279/65 20130101; A61M 15/08 20130101; B01D 46/543
20130101; A62B 23/06 20130101; A61M 2205/0205 20130101 |
International
Class: |
A61M 15/08 20060101
A61M015/08; B01D 46/54 20060101 B01D046/54; B01D 46/00 20060101
B01D046/00; A62B 23/06 20060101 A62B023/06 |
Claims
1. A device for dispensing a compound to air inhaled through a
user's nose, said device comprising a porous membrane disposed over
a support structure defining a three-dimensional hollow shape
containing a filler material imbibed with a volatile compound,
wherein the three-dimensional shape is configured to be inserted
into a user's nostril.
2. The device of claim 1, further comprising a porous membrane
disposed over a support structure defining a three-dimensional
hollow shape containing a filler material imbibed with a volatile
compound, wherein the three-dimensional shape is configured to be
inserted into a user's nostril.
3. The device of claim 1, wherein the membrane is continuous.
4. The device of claim 1, wherein the membrane comprises pores
having a diameter of about 1-25 microns.
5. The device of claim 1, wherein the membrane comprises pores
having a diameter of about 50-500 microns.
6. The device of claim 1, wherein the membrane comprises pores
having a diameter of about 50-300 nanometers.
7. The device of claim 1, wherein the membrane comprises pores
having a diameter of about 0.1-5 mm.
8. The device of claim 1, wherein the inhaled air comprises
allergens, dust particles, viruses, pollution particles and/or
airborne particles resulting from a fire.
9. The device of claim 1, wherein the support structure defines a
cylindrical shape.
10. The device of claim 1, wherein the membrane comprises natural
fibers and/or synthetic fibers, said synthetic fibers comprising at
least one of polyethylene terephthalate (PET), polyethersulfone
(PES), polyvinylidene (PVDF), polytetrafluoroethylene (PTFE,
Teflon), polyamide (nylon), carbon fibers, activated carbon,
cellulose acetate, cellulose nitrate (collodion), mixed-cellulose
esters (MCE), i.e., a mixture of cellulose nitrate/acetate fibers,
polycarbonate, polypropylene (PP), polyacrylonitrile (PAN),
polymethyl methacrylate (PMMA), polyvinyl alcohol (PVA),
polyurethane (PU) and polyvinylchloride (PVC).
11. The device of claim 1 wherein the membrane comprises silver
ions and/or silver nanoparticles to increase an antimicrobial
effect against bacteria and viruses.
12. The device of claim 1, wherein the membrane has electrostatic
properties.
13. The device of claim 1, wherein the membrane is fabricated by
electrospin blowing, fiber weaving, foam casting, injection
molding, compression molding or vacuum forming.
14. The device of claim 1, wherein the filler material is made of
woven mesh fabric, foam, non-woven mesh plastic or fabric, a
sponge, cotton wool or synthetic material.
15. The device of claim 1, wherein the volatile compound comprises
an extract, oil or medicament.
16. The device of claim 1, wherein the medicament treats a chronic
respiratory disease.
17. The device of claim 1, wherein the chronic respiratory disease
is asthma.
18. A method for dispensing a compound to air inhaled through a
user's nose comprising' inserting the device of claim 1 into each
of a user's nostril.
Description
CLAIM OF PRIORITY
[0001] This application claims priority under 35 U.S.C. .sctn. 119
to U.S. provisional application No. 62/807,799 filed on Feb. 20,
2019 in the United States Patent and Trademark Office, the entire
disclosure of which is incorporated herein by reference.
FIELD OF THE EMBODIMENTS
[0002] This invention relates to a 3-dimensional nasal filter pod
for capturing particles present in air inhaled through the
nose.
BACKGROUND OF THE EMBODIMENTS
[0003] The prevalence of chronic inflammation disorders of the
lungs is on the increase. For example, in the U.S. alone, about 1
in 12 people or about 25 million suffer from asthma, of which 6.3
million are children. Indeed, asthma is the third-ranking cause of
hospitalizations for children under the age of 15. It is now well
established that exposure to airborne particles such as animal
dander, dust mites, cockroach particles, pollen, tobacco smoke, air
pollution, and chemical irritants can trigger an asthma episode or
attack resulting in coughing, wheezing, chest tightness, and
difficult breathing. Both long-term and short-term exposure can
cause health problems such as reduced lung function and more asthma
attacks. In the most severe cases, asthma causes the death of more
than 3,600 Americans each year.
[0004] There is an on-going urgent need for devices and methods
that reduce the incidence of or exasperation of chronic respiratory
inflammatory disorders.
[0005] Examples of related art are summarized below.
[0006] U.S. Pat. No. 2,057,397 discloses a nasal inhaler consisting
of a cone or cup with an entry and exit and a filler of absorbent
material such as cotton or wool inserted into the shell
[0007] U.S. Pat. No. 5,568,808 discloses a disposable nose filter
to be inserted in a nostril, including a flexible housing, a filter
component and a flutter valve. The nose filter is adapted to be
easily inserted and removed from the nostril. The flutter valve
forms a seal with the lower exterior portion of the nostril, thus,
forcing air through the filter and preventing air from passing
between the housing and the inner walls of the nostril.
[0008] U.S. Pat. No. 7,354,467 discloses a filtering assembly for
nasal cavities including a connector with two rings connected by a
link, and two filtering members securely connected to the two
rings. The two filtering members are inserted into the wearer's
nasal cavities so as to effectively filter foreign objects from
entering to the wearer's lungs.
[0009] U.S. Pat. No. 7,918,225 discloses a nasal air filtration
device comprising a pair of concave-convex filters, and a support
structure incorporating a pair of generally annular bases for
supporting the filters, and a bridge that couples the bases, to
maintain them in a desired spaced-apart relation and to determine a
desired angular relationship between the bases and between the
associated filters.
[0010] U.S. Pat. No. 8,479,735 discloses a nasal cavity filter
having a substantially cylindrical supporting wall which adheres to
the walls of a nasal cavity, and an inner surface of which defines
a cavity for the passage of air inhaled and exhaled by the user.
The cavity houses a number of fins, which generate turbulence in
the air flowing through, and the surface of which impacted by the
air retains particles present in the air.
[0011] The published U.S. Patent Application 2018/0104518 discloses
a nasal cavity insertion type mask for filtering various kinds of
fine dust contained in external air inhaled through the nose.
[0012] The published U.S. Patent Application 2017/0318874 discloses
methods for the delivery of beneficial respirable compounds such as
moisture, anti-inflammation compounds, anti-irritants, fragrances,
aromatherapy compounds, and low dose medications slowly and
continuously over time using a mask containing a thickened aqueous
gel media delivery system combined with, supported by, and coating
solid bodies inside the filter.
[0013] The published U.S. Patent Application 2009/0229608 discloses
an inhaler comprising a housing to receive an elongate strip of
blisters each containing a dose of medicament and being
sequentially movable into alignment with means for breaching a
blister to enable a user to inhale said dose contained therein.
[0014] U.S. Pat. No. 6,012,455 discloses a nasal air delivery
apparatus configured to deliver breathable air under continuous
positive air pressure to a person who requires such treatment. The
apparatus includes a dentally stabilized platform and a nose mask,
nose piece or nasal tubes resiliently mounted on the platform and
urged toward nasal engagement and rhinal seal. In the case of
configurations including nose masks and nose pieces, the force
applied from the dentally stabilized platform is through a
resilient connection. Various nose masks, nose piece and nostril
engaging air tubes carrying nasal pads are disclosed. In each case,
the resilient mounting on the dentally stabilized platform provides
the necessary air seal. Air which is enhanced by medication or
added oxygen may be supplied by the apparatus.
[0015] U.S. Pat. No. 878,223 discloses an inhaler designed to be
worn continuously, the inhaler itself being inserted in the
nostrils of the wearer, where it is retained in position. When in
use, the cups or capsules are filled with absorbent cotton, bits of
sponge, or any absorbent material, upon which suitable volatile
medicines may be dropped until the absorbent material has become
saturated.
[0016] The International PCT patent application WO2011/041921
discloses a nose mask having a plurality of functions, for example:
to filter pollen and bacteria and the like in the air filtering
function of particles, volatile medicine for treating function of
release, and such as the end of the water-proof function.
[0017] The International PCT patent application WO 2005/035066
discloses a pair of mask bodies; accepting spaces; connection parts
and filter devices, arranged in the nose mask bodies' accepting
space that confer sterilization and bacteriostasis effects.
[0018] U.S. Pat. No. 6,792,945 discloses an inhalation device for
use with a medicament pack in which at least one container for
medicament in powder form is defined between two sheets peelably
secured to one another.
[0019] U.S. Pat. No. 3,698,390 discloses a medicament dispensing
apparatus which includes a first housing and a nozzle of the
convergent-divergent type having an inlet and outlet adjacent the
opposite ends of a nozzle chamber. A reservoir for liquid
medicament is located outside the nozzle chamber adjacent the
throat of the nozzle, and a metering and dispensing valve is
positioned adjacent the throat for injecting a measured amount of
medicament from the reservoir into the nozzle. Upon inhaling at the
outlet of the nozzle the medicament injected into the nozzle is
drawn into the mouth of the patient.
[0020] None of the art described above addresses all of the issues
that the present invention does.
[0021] For example, none of the references disclose a device
comprising a porous continuous membrane disposed over a support
structure defining a three-dimensional hollow shape configured to
be inserted into a user's nostril and house a filler containing an
inhalable compound.
SUMMARY OF THE EMBODIMENTS
[0022] In a first aspect, a device for dispensing a compound to air
inhaled through a user's nose is disclosed that comprises a porous
membrane disposed over a support structure defining a
three-dimensional hollow shape containing a filler material imbibed
with a volatile compound, wherein the three-dimensional shape is
configured to be inserted into a user's nostril.
[0023] In a second aspect, a device for dispensing a compound to
air inhaled through a user's nose is disclosed that consists of a
porous membrane disposed over a support structure defining a
three-dimensional hollow shape containing a filler material imbibed
with a volatile compound, wherein the three-dimensional shape is
configured to be inserted into a user's nostril.
[0024] In certain embodiments of the first or second aspect, the
membrane is continuous.
[0025] In certain embodiments of the first or second aspect, the
device's membrane comprises pores having a diameter of about 50-500
microns.
[0026] In certain embodiments of the first or second aspect, the
device's membrane comprises pores having a diameter of about 1-25
microns.
[0027] In certain embodiments of the first or second aspect, the
membrane comprises pores having a diameter of about 1-10
microns.
[0028] In certain embodiments of the first or second aspect, the
membrane comprises pores having a diameter of about 1 micron.
[0029] In certain embodiments of the first or second aspect, the
device's membrane comprises pores having a diameter of about 50-300
nanometers.
[0030] In certain embodiments of the first or second aspect, the
device's membrane comprises pores having a diameter of about a
0.1-5 millimeters.
[0031] In certain embodiments of the first or second aspect, the
inhaled air comprises allergens, dust particles, viruses, pollution
particles and/or airborne particles, for example, resulting of
combustion such as the ones resulting from forest fires. In certain
embodiments of the first or second aspect, the support structure
defines a cylindrical shape.
[0032] In certain embodiments of the first or second aspect, the
membrane comprises natural or synthetic fibers. In certain
embodiments, the synthetic fibers may comprise at least one of
polyethylene terephthalate (PET), polyethersulfone (PES),
polyvinylidene (PVDF), polytetrafluoroethylene (PTFE, Teflon),
polyamide (nylon), carbon fibers, activated carbon, cellulose
acetate, cellulose nitrate (collodion), mixed-cellulose esters
(MCE), i.e., a mixture of cellulose nitrate/acetate fibers,
polycarbonate, polypropylene (PP), polyacrylonitrile (PAN),
polymethyl methacrylate (PMMA), polyvinyl alcohol (PVA),
polyurethane (PU) or polyvinylchloride (PVC).
[0033] In certain embodiments of the first or second aspect, the
membrane has electrostatic properties.
[0034] In certain embodiments of the first or second aspect, the
membrane is fabricated by electrospin blowing, fiber weaving, foam
casting, injection molding, compression molding or vacuum
forming.
[0035] In certain embodiments of the first or second aspect, the
filler material is made of woven mesh fabric, foam, non-woven mesh
plastic or fabric, a sponge, cotton wool or synthetic material.
[0036] In certain embodiments of the first or second aspect, the
volatile compound comprises an extract, oil or medicament.
[0037] In certain embodiments, the medicament treats a chronic
respiratory disease such as asthma.
[0038] In a third aspect, a method for dispensing a compound to air
inhaled through a user's nose is disclosed comprising inserting the
device of any one of the preceding embodiments into each of a
user's nostril.
BRIEF DESCRIPTION OF THE DRAWINGS
[0039] FIGS. 1A and 1B show exemplary perspective views of certain
embodiments of a 3-dimensional nasal filter pod.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0040] The preferred embodiments of the present invention will now
be described with reference to the drawings. Identical elements in
the various figures are identified with the same reference
numerals.
[0041] As used herein, the singular forms "a," "an," and "the," are
intended to include the plural forms as well, unless the context
clearly indicates otherwise.
[0042] The phrase "and/or," as used herein in the specification and
in the claims, should be understood to mean "either or both" of the
elements so conjoined, i.e., elements that are conjunctively
present in some cases and disjunctively present in other cases.
Thus, as a non-limiting example, a reference to "A and/or B", when
used in conjunction with open-ended language such as "comprising"
can refer, in one embodiment, to A only (optionally including
elements other than B); in another embodiment, to B only
(optionally including elements other than A); in yet another
embodiment, to both A and B (optionally including other elements);
etc.
[0043] As used herein in the specification and in the claims, the
phrase "at least one," in reference to a list of one or more
elements, should be understood to mean at least one element
selected from any one or more of the elements in the list of
elements, but not necessarily including at least one of each and
every element specifically listed within the list of elements and
not excluding any combinations of elements in the list of elements.
This definition also allows that elements may optionally be present
other than the elements specifically identified within the list of
elements to which the phrase "at least one" refers, whether related
or unrelated to those elements specifically identified. Thus, as a
non-limiting example, "at least one of A and B" (or, equivalently,
"at least one of A or B," or, equivalently "at least one of A
and/or B") can refer, in one embodiment, to at least one,
optionally including more than one, A, with no B present (and
optionally including elements other than B); in another embodiment,
to at least one, optionally including more than one, B, with no A
present (and optionally including elements other than A); in yet
another embodiment, to at least one, optionally including more than
one, A, and at least one, optionally including more than one, B
(and optionally including other elements); etc.
[0044] When the term "about" is used in conjunction with a
numerical range, it modifies that range by extending the boundaries
above and below those numerical values. In general, the term
"about" is used herein to modify a numerical value above and below
the stated value by a variance of 20%, 10%, 5%, or 1%. In certain
embodiments, the term "about" is used to modify a numerical value
above and below the stated value by a variance of 10%. In certain
embodiments, the term "about" is used to modify a numerical value
above and below the stated value by a variance of 5%. In certain
embodiments, the term "about" is used to modify a numerical value
above and below the stated value by a variance of 1%.
[0045] When a range of values is listed herein, it is intended to
encompass each value and sub-range within that range. For example,
"1-5 ng" is intended to encompass 1 ng, 2 ng, 3 ng, 4 ng, 5 ng, 1-2
ng, 1-3 ng, 1-4 ng, 1-5 ng, 2-3 ng, 2-4 ng, 2-5 ng, 3-4 ng, 3-5 ng,
and 4-5 ng.
[0046] It will be further understood that the terms "comprises,"
"comprising," "includes," and/or "including," when used herein,
specify the presence of stated features, integers, steps,
operations, elements, and/or components, but do not preclude the
presence or addition of one or more other features, integers,
steps, operations, elements, components, and/or groups thereof.
Reference will now be made in detail to each embodiment of the
present invention. Such embodiments are provided by way of
explanation of the present invention, which is not intended to be
limited thereto. In fact, those of ordinary skill in the art may
appreciate upon reading the present specification and viewing the
present drawings that various modifications and variations can be
made thereto.
[0047] As used herein, the terms "treat," "treatment" or "treating"
refer to therapeutic treatments, wherein the object is to reverse,
alleviate, ameliorate, inhibit, slow down or stop the progression
or severity of a disorder, e.g. a respiratory disorder. The term
"treating" includes reducing or alleviating at least one adverse
effect or symptom of a condition, disease or disorder associated
with a disorder, e.g. a respiratory disorder. Treatment is
generally "effective" if one or more symptoms or clinical markers
are reduced. Alternatively, treatment is "effective" if the
progression of the disorder is reduced or halted. That is,
"treatment" includes not just the improvement of symptoms or
markers, but also a cessation of, or at least slowing of, progress
or worsening of symptoms compared to what would be expected in the
absence of treatment. Beneficial or desired clinical results
include, but are not limited to, alleviation of one or more
symptom(s), diminishment of extent of disease, stabilized (i.e.,
not worsening) state of disease, delay or slowing of disease
progression, amelioration or palliation of the disease state,
remission (whether partial or total), and/or decreased mortality,
whether detectable or undetectable. The term "treatment" also
includes providing relief from the symptoms or side-effects of a
disorder, e.g. a respiratory disorder (including palliative
treatment).
[0048] In certain embodiments, the terms "treat," "treatment" or
"treating" refer to therapeutic treatments, wherein the object is
to reverse, alleviate, ameliorate, inhibit, slow down or stop the
progression or severity of a disorder that is not a respiratory
disorder. The term "treating" includes reducing or alleviating at
least one adverse effect or symptom of a condition, disease or
disorder associated with a disorder that is not a respiratory
disorder. For example, the filler material may comprise a
medicament for the treatment of a disorder that is not a
respiratory disorder.
[0049] FIG. 1A depicts an exemplary perspective view of a
3-dimensional nasal filter pod 8 having a top 1, side 2, bottom
entrance 10 and an interior cavity 9. The porous membrane 7 can
have a flange 3 that attaches to a circular support base 5.
Protrusions 4 at the periphery of the circular support base 5 help
to keep the nasal filter pod in place after insertion into the
nasal cavity.
[0050] FIG. 1B shows an exemplary perspective view of a
3-dimensional nasal filter pod 8 showing the support structure 6
beneath the porous membrane 7.
[0051] In certain embodiments, attachment of the porous membrane 7
to the support base 5 may include, but is not limited to, press
fit, slip fit, adhesive, threading, clamps, double-sided tape,
heat-seal, high-frequency welding or magnetic attachment.
[0052] In certain embodiments, the porous membrane 7 can be
manufactured with an electro spin blowing manufacturing process to
form a flat 2D membrane that can be molded into a 3-dimensional
structure.
[0053] In certain embodiments, the porous membrane 7 can be
manufactured by a process including, but not limited to fiber
weaving, foam casting, injection molding, compression molding or
vacuum forming.
[0054] In certain embodiments, the porous membrane 7 can be made of
natural and/or synthetic fibers. In certain embodiments, the
synthetic fibers may include, but is not limited to, at least one
of polyethylene terephthalate (PET), polyethersulfone (PES),
polyvinylidene (PVDF), polytetrafluoroethylene (PTFE, Teflon),
mixed-cellulose esters (MCE), polyimide (nylon), natural fibers,
carbon fibers, or activated carbon, cellulose acetate, cellulose
nitrate (collodion), mixed-cellulose esters (MCE, i.e., a mixture
of cellulose nitrate/acetate fibers), polycarbonate, polypropylene
(PP), polyacrylonitrile (PAN), polymethyl methacrylate (PMMA),
polyvinyl alcohol (PVA), polyurethane (PU) and polyvinylchloride
(PVC). In certain embodiments, the porous membrane 7 may comprise
chitosan, collagen, polylactic acid (PLA) and/or
Poly(lactic-co-glycolic acid) (PLGA). In certain embodiments, the
porous membrane 7 can include activated carbon conferring
electrostatic charge to the membrane.
[0055] In certain embodiments, the porous membrane 7 can include
silver ions and silver nanoparticles to increase the antimicrobial
effect of the overall filtration against bacteria and viruses.
[0056] In certain embodiments, the inhaled air comprises allergens,
dust particles, viruses, pollution particles such as the ones
classified under the particulate matter, pm2.5 denomination, and/or
airborne particles resulting of combustion such as the ones
resulting from forest fires.
[0057] In certain embodiments, the porous membrane 7 can have a
3-dimensional (3D) structure, in that it is not limited to a single
shape that is cut-out, formed or created as part of or from a two
(2) dimensional substrate, such as sheet of paper or a sheet of
foam.
[0058] In certain embodiments, the porous membrane 7 can have a
3-dimensional shape that creates a maximum surface area for air to
flow through, thus decreasing the pressure drop between the air
pressure at the entrance of the nasal filter 10 and the pressure at
the top 1 of the nasal filter pod 8.
[0059] In certain embodiments, the 3-dimensional shape defines a
hollow cavity 9.
[0060] In certain embodiments, the structural integrity of the
nasal filter pod 8 can be re-enforced by a support structure 6 on
which the porous membrane 7 can be seated or inserted, stuffed,
trapped, encapsulated, merged, woven, or other any means of
attachment.
[0061] In certain embodiments, methods of attaching the porous
membrane 7 to the support structure 6 and support base 5 include,
but are not limited to, gluing, bonding, heat staking, melting,
friction welding, vibration welding, sonic welding or insert
molding (also referred to as overmolding).
[0062] In certain embodiment, the porous membrane 7 has pores with
an average diameter of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20
or 25 microns.
[0063] In certain embodiment, the porous membrane 7 has pores with
an average diameter ranging from 50 to 300 nm.
[0064] In certain embodiment, the porous membrane 7 has pores with
an average diameter ranging 0.1 to 5 mm.
[0065] n certain embodiment, the porous membrane 7 can have a
thickness of about 0.1, .0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,
2, 3, 4, 5, 6, 7, 8, 9, or 10 mm.
[0066] In certain embodiments, the porous membrane 7 is continuous,
e.g., made from a single piece of material.
[0067] In certain embodiments, the hollow cavity 9 of the nasal
filter pod 8 may contain a porous filler material.
[0068] In certain embodiments, the porous filler material can be
made of, for example, a porous woven mesh fabric, foam, non-woven
mesh plastic or fabric, a sponge, cotton wool and/or synthetic
material.
[0069] In certain embodiments, the porous filler material can
contain a volatile compound such as an oil extract, vapor, scented
powder or liquid and/or medicament that is slowly released into the
air inhaled through the user's nostril.
[0070] In certain embodiments, the porous filler material can be
imbibed with a powdered or liquid medication, for example, for the
treatment of a chronic respiratory illness such as asthma.
[0071] In certain embodiments, the porous filler material
containing a medicament may be transferable to devices such as
masks or air-purifier like products.
[0072] Although this invention has been described with a certain
degree of particularity, it is to be understood that the present
disclosure has been made only by way of illustration and that
numerous changes in the details of construction and arrangement of
parts may be resorted to without departing from the spirit and the
scope of the invention.
* * * * *